Financing ·
Radiopharm Theranostics issues 140M options under employee incentive scheme
RADXRadiopharm Theranostics Ltd
Radiopharm Theranostics issued 140,028,000 unquoted options to employees on October 19, 2026, under its Omnibus Incentive Plan. The issuance was exempt from shareholder approval under ASX Listing Rule 7.2(13). Key management personnel received a significant portion of the grant, with Dimitris Voliotis allocated 30,887,000 options. Concurrently, four directors cancelled a total of 4,888,888 listed options due to expiration or cancellation. The company develops and commercializes radiopharmaceuticals for diagnostic imaging and targeted radionuclide therapy.